רווח תפעולי לפני ניכוי פחת: adagene.com (ADAG)

Adagene maintains a high reputation for creating innovative antibodies, and analyzing the EBITDA chart in GURU.Markets, we note that the value is fixed at 0.00. Liquidity is sustained through partnership payments that cover R&D costs, while the precision protein design via the NEObody system minimizes drug toxicity for cancer therapies.

For Adagene (ADAG), which is developing the SAFEbody platform and conducting clinical trials in oncology, operating profit reflects the efficiency of intellectual property monetization and licensing agreements. This indicator filters out market noise, forming stable consolidation zones that allow investors to differentiate the fundamental trend from short-term fluctuations through absolute EBITDA dynamics. A breakout below the lower boundaries of this range serves as a signal of a critical increase in capital risks.